Grazia Pennisi

Finally out the @sigeitalia position paper on the management of GLP-1RAs in gastroenterology. 10 GRADE statements 4 areas covered (hepatology, endoscopy, cancer incidence, and GI AEs) @TacelliMatteo @ZanettoAlberto @gra_penni @Ivoboskoski @lelecapurso @MarcelloMaida

Fantastic #GUTVideo by @JimmyLaiCT @TerryYip12 @CUHKMedicine @CUHKGI on the paper by Lai et al entitled "Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease" via bit.ly/44k5yMY Paper accessed via bit.ly/4iUnp32 @hanneshagstrom @wonglaihung @gra_penni @AngeloArmandi @YingShang1 @mromerogomez #HCC #MASLD

Fantastic #GUTVideo by @JimmyLaiCT @TerryYip12 @CUHKMedicine @CUHKGI on the paper by Lai et al entitled "Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease" via bit.ly/44k5yMY Paper accessed via bit.ly/4iUnp32 @hanneshagstrom @wonglaihung @gra_penni @AngeloArmandi @YingShang1 @mromerogomez #HCC #MASLD

Proud to share our recent publication @JHepatology This is the first international multicenter study evaluating the clinical and prognostic impact of the first and further decompensation in patients with #MASLD. Grateful to all collaborators!

Read the #GUTOnline paper by Lai et al on "Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease" via bit.ly/3FObRzm #MASLD #HCC @hanneshagstrom @wonglaihung @gra_penni @AngeloArmandi @YingShang1 @mromerogomez @TerryYip12

➡️Pleased to coauthor this excellent work! 🟢Language does not affect #ChatGPT ability to counsel #MASLD patients ❌Suboptimal accuracy on specialist referral @nicolapugliese_ @HumanitasMilano @JPM_MDPI @McGill_DOM @cusm_muhc @RIMUHC1 @CASLupdates @FRQS1 mdpi.com/2075-4426/14/6…

A landmark cohort study of 16,603 #MASLD patients finds #VCTE-based scores outperform most noninvasive tests and match or exceed histologic staging in predicting liver-related events. Stable over time, improved scores linked to lower risk events, positioning VCTE as a viable liver biopsy alternative in routine clinical practice and in Phase 2b & 3 clinical trials→shorturl.at/fBEX4 @JAMA_current @HuapengLin @TerryYip12 @salvatore_petta @HannesHagstrom @DrJLCalleja @RocioGallegoD @ArunJSanyalVCU @phil_newsome7 @ldcastera @wonglaihung @gra_penni @AngeloArmandi @MarcdeSAIN43075 @ElbaLlop @kevinkjteh @mromerogomez @VWSWong #livertwitter #MASH #SLD #AgileScore

😊Pleased to be part of this paper in @HEP_Journal ✅#liver stiffness ≥10kPa or AGILE 3+ >0.67 may identify patients with #MASLD for inclusion in clinical trials journals.lww.com/hep/abstract/2… @CanNASHNetwork @McGill_DOM @cusm_muhc @CASLupdates @RIMUHC1 #livertwitter @FRQS1 @gra_penni

Are you wondering how ANGPTL3 inhibition may cause steatotic liver disease? Pennisi and Maurotti show an increase in intracellular lipids and signs of hypothyroidism after downregulation of ANGPTL3 in human hepatocytes ahajrnls.org/3VgVBfg

Insights from our latest publication on ANGPTL3 downregulation effect on human hepatocytes @atvbahajournals

We investigated a genetic variation (rs2642438) that protects against liver diseases. This causes a single amino acid change in MARC1 protein and results in its lower protein levels, making it less effective. Read full paper @LiverInt @stefano_romeo76 onlinelibrary.wiley.com/doi/full/10.11…

Our paper on the #agile3+score for the identification of #liverfibrosis in #masld published in @HEP_Journal Thanks to @andreadalbeni for sharing this first co-authorship @Alessan95336031 @gra_penni @salvatore_petta @FedRavaioli 👉🏻 surl.li/nhjdg

Honoured to coauthor this important publication in @HEP_Journal! Risk of #liver-related events similar in high-risk #MASH and liver #fibrosis without MASH. @CASLupdates @McGill_DOM @mcgillu @gra_penni @mromerogomez @VWSWong @docberza @salvatore_petta 👉journals.lww.com/hep/abstract/9…

🎉 Excited to share our latest meta-analysis on the diagnostic accuracy of #AGILE3+ score by @Echosens for advanced #fibrosis in #MASLD patients at #SLDSummit! 📊🔍 Huge kudos to the amazing team and collaboration 👏 Stay tuned for the publication update! 📚 @EASLedu @EASLnews